Stock Chart

SLS

$7.42 +13.63%
Score: 62.8 BUY
LEAPs: SELL $7
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $7
Premium: $2.40
Expiry: Jan 15, 2027
Target: $7
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $7.11 - $7.78 UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.49
Vol: 2.90x (vs SPY: 3.1x | vs QQQ: 3.4x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About SLS - SELLAS Life Sciences Group, Inc. Common Stock

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Key Statistics

Market Cap $1B

This SLS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track SLS's price movements with trendlines, gamma walls, and key support/resistance levels.